23.3 C
New York
Thursday, September 23, 2021

Aeterna Zentaris Inc. (AEZS) stock gains today. Why did it happen?

Aeterna Zentaris Inc. (AEZS) on March 15, 2020, announced the Exclusive License agreement and Research contract with Julius-Maximilians-University Wuerzburg for the COVID-19 vaccine after which the AEZS stock price saw a push of 14.41% to reach $1.35 a share at the time of this writing. The AEZS stock was down by 4.84% at the previous closing with a $1.180 per share price. Let’s see the details of the agreement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


What’s Happening?

Aeterna Zentaris Inc. is a biopharmaceutical company involved in the development and commercializing of pharmaceutical therapeutics to treat oncology and endocrinology. AEZS announced today that it has entered into an exclusive license agreement for the development of Oral Prophylactic Bacterial Vaccine against COVID-19. The vaccine was invented in Julius-Maximilians-University Wuerzburg, a German University, and currently in the phase of preclinical development. AEZS has also announced a research contract with the university for supplementary research and study of preclinical development Oral Prophylactic Bacterial COVID-19 Vaccine

The potential COVID-19 vaccine developed in Julius-Maximilians-University Wuerzburg is orally active and uses the Salmonella Typhi Ty21a, a typhoid fever vaccine, as a carrier strain. salmonella Typhi Ty21a is safe, effective, and easy to handle having a temperature range of 2°C to 8°C This Furthermore, this vaccine relies on SARS-CoV-2 antigens to improve the immunity against mutated viruses.

AEZS announced on March 11, 2021, that it will continue to expand its developing pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) to treat Primary Hypoparathyroidism.


More than 116 million confirmed COVID-19 cases and more than 2.5 million deaths have been recorded after the spread of the coronavirus pandemic. Many companies have prepared vaccines against COVID-19 but still, there is no definite cure against COVID-19. In such a scenario, the potential orally active vaccine developed by Aeterna Zentaris in Julius-Maximilians-University Wuerzburg can be a game-changer in the future as it has the potential to be cost-effective with less demanding storage requirements. Hence AEZS stock can be a good bet for investors in the future. 

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.